- Home
- INBX vs GHRS Comparison
INBX vs GHRS Comparison
Compare INBX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | GHRS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 947.2M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INBX | GHRS |
|---|---|---|
| Price | $80.86 | $21.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $150.00 | $41.38 |
| AVG Volume (30 Days) | ★ 220.4K | 120.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $10.90 | $8.75 |
| 52 Week High | $94.57 | $19.51 |
Technical Indicators
Market Signals| Indicator | INBX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 81.35 |
| Support Level | $71.31 | $12.44 |
| Resistance Level | $85.97 | N/A |
| Average True Range (ATR) | 5.48 | 1.18 |
| MACD | 2.29 | 0.64 |
| Stochastic Oscillator | 71.98 | 72.08 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.